Company profile
Ardelyx, Inc.
NASDAQ: ARDX · Healthcare · Biotechnology
#228 of 1,418 Healthcare companies by revenue68th-percentile growth
EA Score
68BFH 56DQ 86GM 63SS 72
v0.1 · 65/100 weight · provisional
↑ filing timeliness, 3-yr revenue growth · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$427.7M
Rev growth YoY (TTM)
+18.2%
Net income (FY)
-$61.6M
Employees
489
as of 2026-08-10
Market cap
$988.1M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$407.3M$407.3M2025
Net income-$61.6M-$61.6M2025
Operating income-$41.0M-$41.0M2025
Total assets$501.6M$501.6M2025
Liabilities$334.7M$334.7M2025
Equity$166.9M$166.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product57%
Product, IBSRELA42%
License1%
By geography
UNITED STATES93%
Asia Pacific7%
North America0%
The read
What is Ardelyx, Inc.’s revenue?
Ardelyx, Inc. booked $407.3M in FY2025 revenue, growing 22% year over year — faster than most Healthcare companies we track, at a -15.1% net margin.
Peers · Healthcare
Certara, Inc.68BMiMedx Group, Inc.85AInnoviva, Inc.83B+Esperion Therapeutics, Inc.61CKrystal Biotech, Inc.77B+Sonida Senior Living, Inc.64CNeighbors
Middlesex →Key facts
CEOMichael G. Raab
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: ARDX
Employees489
IPO date2014-06-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.